

FIG.1A-1M: Spheroid Growth in KRAS G12C vs. KRAS G12S NSCLC Cell Lines




FIG. 1A




FIG. 1B




FIG. 1C








FIG. 1D

**FIG. 1E****FIG. 1F**






FIG. 1I






FIG. 1J






FIG. 1M

FIG.2A-2B:Spheroid Growth in Dox-Inducible shRHEB KRAS G12C NSCLC Cell Lines




FIG. 2A




FIG. 2B

FIG.3A-3G: 3D and 2D Signaling in KRAS G12C NSCLC Cell Lines





FIG. 3A






FIG. 3C




FIG. 3D




FIG. 3E




FIG. 3F




FIG. 3G

FIG.4A-4C: Tumor Growth over Time in NCI-H2122 NSCLC Model




FIG. 4A




FIG. 4B




FIG. 4C

FIG.5A-5C: Tumor Growth over Time in LU2512 NSCLC Model




FIG. 5A



**FIG. 5B****FIG. 5C**

FIG.6A-6C: Tumor Growth over Time in NCI-H2030 NSCLC Model




FIG. 6A




FIG. 6B




FIG. 6C

FIG.7A-7B: Duration of Response in NCI-H2030 NSCLC Model




FIG. 7A




FIG. 7B

FIG.8A-8B: IHC Immunostaining Images from Treated Cells from NCI-H2122 NSCLC Model




FIG. 8A




FIG. 8B

FIG.9A-9C: Signaling and IHC Results from NCI-H2122 KRAS G12C NSCLC Model




FIG. 9A




FIG. 9B




FIG. 9C

FIG.10A-10B: Tumor Growth over Time in PDAC Models




FIG. 10A




FIG. 10B




FIG. 11

FIG.12A-12E: Tumor Growth over Time in CRC Models




FIG. 12A




FIG. 12B




FIG. 12C





FIG. 12D

**FIG. 12E**

Immunoblot Analysis of Treated GP2D CDX Model Cells




FIG. 13

FIG.14A-14B: Tumor Growth over Time in PDAC Models




FIG. 14A




FIG. 14B

FIG.15A-15D: Tumor Growth over Time in CRC Models




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D

FIG.16A-16B: Tumor Growth over Time in NCI-H358 NSCLC Model




FIG. 16A




FIG. 16B

FIG.17A-17F: Tumor Growth over Time in NCI-H2122 NSCLC Model




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D




FIG. 17E




FIG. 17F

FIG.18A-18E: Tumor Growth Over Time in NCI-H2030 and NCI-H2122 NSCLC Model




FIG. 18A






FIG. 18B






FIG. 18E

FIG.19A-19B: Signaling in KRAS G12C Pretreated Tumors





FIG. 19A



NCI-H2122
(*KRAS*^{G12C}) NSCLC CDX

FIG. 19B




FIG. 20




FIG. 21

FIG.22A-22B: Tumor Growth over Time in KRAS G12V PDAC Models

